Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups

Basit Öğe Kaydı
dc.authorid0000-0002-7071-2471
dc.contributor.authorSezer, A.
dc.contributor.authorKılıçkap, S.
dc.contributor.authorGümüş, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorHe, X.
dc.date.accessioned2025-05-10T19:48:32Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.description.sponsorshipEuropean Soc Med Oncol
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.; Sanofi
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc., and Sanofi.
dc.identifier.doi10.1016/j.annonc.2022.07.1306
dc.identifier.endpageS1089
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.issue7
dc.identifier.scopusqualityQ1
dc.identifier.startpageS1089
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2022.07.1306
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11741
dc.identifier.volume33
dc.identifier.wosWOS:000866211601445
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.titlePatient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups
dc.typeConference Object

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
11741.pdf
Boyut:
103.91 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu